Compare Novartis AG (NVS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Regeneron Pharmaceuticals Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Regeneron Pharmaceuticals Inc trades at $680.5 (market cap $70.47B). The key difference: Novartis AG is far larger — about 4.1× Regeneron Pharmaceuticals Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | REGN | |
|---|---|---|
Market Cap | $290.25B | $70.47B |
Sector | Health | Health |
52-Week High | $168.62 | $812.27 |
52-Week Low | $113.50 | $545.46 |
Enterprise Value | $330.27B | $64.42B |
Dividend Yield | 3.17% | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
